Dnb Asset Management As Has Trimmed Kellogg Co (K) Stake; Entellus Medical (ENTL) Shorts Lowered By 3.59%

Dnb Asset Management As decreased Kellogg Co (K) stake by 63.84% reported in 2017Q3 SEC filing. Dnb Asset Management As sold 64,845 shares as Kellogg Co (K)’s stock declined 2.57%. The Dnb Asset Management As holds 36,735 shares with $2.29 million value, down from 101,580 last quarter. Kellogg Co now has $23.21B valuation. The stock increased 0.83% or $0.55 during the last trading session, reaching $67.17. About 2.14M shares traded. Kellogg Company (NYSE:K) has declined 5.60% since January 23, 2017 and is downtrending. It has underperformed by 22.30% the S&P500.

Entellus Medical Incorporated (NASDAQ:ENTL) had a decrease of 3.59% in short interest. ENTL’s SI was 2.23 million shares in January as released by FINRA. Its down 3.59% from 2.32 million shares previously. With 114,400 avg volume, 20 days are for Entellus Medical Incorporated (NASDAQ:ENTL)’s short sellers to cover ENTL’s short positions. The SI to Entellus Medical Incorporated’s float is 24.7%. The stock increased 0.04% or $0.01 during the last trading session, reaching $24.05. About 1.11M shares traded or 209.71% up from the average. Entellus Medical, Inc. (NASDAQ:ENTL) has declined 17.59% since January 23, 2017 and is downtrending. It has underperformed by 34.29% the S&P500.

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company has market cap of $612.65 million. The firm offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It currently has negative earnings. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat physicians to access the frontal sinus and trans-illuminate the sinus cavity; Maxillary Seeker, a tool that allow users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium.

Among 6 analysts covering Entellus Medical (NASDAQ:ENTL), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Entellus Medical has $27 highest and $17.0 lowest target. $21.25’s average target is -11.64% below currents $24.05 stock price. Entellus Medical had 9 analyst reports since August 9, 2015 according to SRatingsIntel. As per Tuesday, September 29, the company rating was maintained by Piper Jaffray. Deutsche Bank initiated the shares of ENTL in report on Thursday, October 6 with “Buy” rating. As per Tuesday, June 14, the company rating was initiated by BTIG Research. The firm earned “Hold” rating on Friday, December 8 by William Blair. The firm has “Hold” rating by Canaccord Genuity given on Monday, October 16. The firm earned “Buy” rating on Monday, August 21 by Piper Jaffray. Canaccord Genuity maintained Entellus Medical, Inc. (NASDAQ:ENTL) on Sunday, August 9 with “Buy” rating.

Since December 13, 2017, it had 0 insider buys, and 1 insider sale for $165.17 billion activity. KELLOGG W K FOUNDATION TRUST also sold $165.17 billion worth of Kellogg Company (NYSE:K) shares.

Dnb Asset Management As increased Lyondellbasell Industries Nv stake by 12,900 shares to 429,522 valued at $42.54 million in 2017Q3. It also upped Hewlett Packard Enterprise Co stake by 407,027 shares and now owns 4.33 million shares. Blackrock Inc (NYSE:BLK) was raised too.

Analysts await Kellogg Company (NYSE:K) to report earnings on February, 8 before the open. They expect $0.96 EPS, up 4.35% or $0.04 from last year’s $0.92 per share. K’s profit will be $331.65M for 17.49 P/E if the $0.96 EPS becomes a reality. After $1.05 actual EPS reported by Kellogg Company for the previous quarter, Wall Street now forecasts -8.57% negative EPS growth.